Corcept Therapeutics Incorporated Company Profile (NASDAQ:CORT)

About Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated logoCorcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:CORT
  • CUSIP: 21835210
  • Web: www.corcept.com
Capitalization:
  • Market Cap: $1.98559 billion
  • Outstanding Shares: 113,397,000
Average Prices:
  • 50 Day Moving Avg: $15.54
  • 200 Day Moving Avg: $12.18
  • 52 Week Range: $5.94 - $18.54
P/E:
  • Trailing P/E Ratio: 90.55
  • Foreward P/E Ratio: 25.28
  • P/E Growth: 0.57
Sales & Book Value:
  • Annual Revenue: $108.69 million
  • Price / Sales: 18.99
  • Book Value: $0.58 per share
  • Price / Book: 31.38
Profitability:
  • EBIDTA: $25.67 million
  • Net Margins: 22.28%
  • Return on Equity: 51.45%
  • Return on Assets: 33.01%
Debt:
  • Current Ratio: 3.99%
  • Quick Ratio: 3.84%
Misc:
  • Average Volume: 1.14 million shs.
  • Beta: 2.07
  • Short Ratio: 10.59
 

Frequently Asked Questions for Corcept Therapeutics Incorporated (NASDAQ:CORT)

What is Corcept Therapeutics Incorporated's stock symbol?

Corcept Therapeutics Incorporated trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics Incorporated's earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings data on Tuesday, August, 1st. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.02. The company had revenue of $35.56 million for the quarter, compared to analysts' expectations of $31.37 million. Corcept Therapeutics Incorporated had a return on equity of 51.45% and a net margin of 22.28%. The business's revenue was up 80.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.01 EPS. View Corcept Therapeutics Incorporated's Earnings History.

When will Corcept Therapeutics Incorporated make its next earnings announcement?

Corcept Therapeutics Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Corcept Therapeutics Incorporated.

Where is Corcept Therapeutics Incorporated's stock going? Where will Corcept Therapeutics Incorporated's stock price be in 2017?

5 brokerages have issued twelve-month price objectives for Corcept Therapeutics Incorporated's stock. Their forecasts range from $7.00 to $24.00. On average, they expect Corcept Therapeutics Incorporated's stock price to reach $16.60 in the next twelve months. View Analyst Ratings for Corcept Therapeutics Incorporated.

Who are some of Corcept Therapeutics Incorporated's key competitors?

Who are Corcept Therapeutics Incorporated's key executives?

Corcept Therapeutics Incorporated's management team includes the folowing people:

  • James N. Wilson, Independent Chairman of the Board
  • Joseph K. Belanoff M.D., President, Chief Executive Officer, Director
  • Gary Charles Robb, Chief Financial Officer, Secretary
  • Robert S. Fishman M.D., Chief Medical Officer
  • G. Leonard Baker Jr., Independent Director
  • Daniel M. Bradbury, Independent Director
  • Renee D. Gala, Independent Director
  • David L. Mahoney, Independent Director
  • Daniel N. Swisher Jr., Independent Director

Who owns Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Federated Investors Inc. PA (12.49%), Ingalls & Snyder LLC (6.46%), Vanguard Group Inc. (3.92%), Renaissance Technologies LLC (2.37%), State Street Corp (1.79%) and Acadian Asset Management LLC (1.50%). Company insiders that own Corcept Therapeutics Incorporated stock include Daniel Bradbury, David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright and Steven Lo. View Institutional Ownership Trends for Corcept Therapeutics Incorporated.

Who sold Corcept Therapeutics Incorporated stock? Who is selling Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Federated Investors Inc. PA, Lord Abbett & CO. LLC, GSA Capital Partners LLP, Menta Capital LLC, Arrowstreet Capital Limited Partnership, Wells Fargo & Company MN and Numeric Investors LLC. Company insiders that have sold Corcept Therapeutics Incorporated stock in the last year include David L Mahoney, James N Wilson, Joseph K Belanoff and Patrick G Enright. View Insider Buying and Selling for Corcept Therapeutics Incorporated.

Who bought Corcept Therapeutics Incorporated stock? Who is buying Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Renaissance Technologies LLC, Vanguard Group Inc., Teachers Advisors LLC, Prudential Financial Inc., Acadian Asset Management LLC, Russell Investments Group Ltd. and State Street Corp. Company insiders that have bought Corcept Therapeutics Incorporated stock in the last two years include G Leonard Baker Jr and Gary Charles Robb. View Insider Buying and Selling for Corcept Therapeutics Incorporated.

How do I buy Corcept Therapeutics Incorporated stock?

Shares of Corcept Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corcept Therapeutics Incorporated's stock price today?

One share of Corcept Therapeutics Incorporated stock can currently be purchased for approximately $18.20.


MarketBeat Community Rating for Corcept Therapeutics Incorporated (NASDAQ CORT)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Corcept Therapeutics Incorporated (NASDAQ:CORT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $16.60 (8.79% downside)

Analysts' Ratings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/8/2017Piper Jaffray CompaniesBoost Price TargetBuy$18.00 -> $24.00LowView Rating Details
8/31/2017Stifel NicolausInitiated CoverageBuy -> Buy$20.00HighView Rating Details
7/18/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$15.00 -> $20.00LowView Rating Details
12/20/2016Janney Montgomery ScottInitiated CoverageSell$7.00N/AView Rating Details
11/2/2016FBR & CoSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Earnings by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Earnings History by Quarter for Corcept Therapeutics Incorporated (NASDAQ CORT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017$0.09N/AView Earnings Details
8/1/2017Q2 2017$0.08$0.10$31.37 million$35.56 millionViewN/AView Earnings Details
5/1/2017Q1 2017$0.03$0.04$25.53 million$27.60 millionViewListenView Earnings Details
3/6/2017Q4 2016$0.04$0.04$23.85 million$23.81 millionViewN/AView Earnings Details
11/1/2016Q316$0.01$0.02$21.24 million$21.70 millionViewN/AView Earnings Details
1/28/2016Q415($0.02)$0.01$15.50 million$15.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.02)($0.01)$13.90 million$13.30 millionViewN/AView Earnings Details
8/5/2015Q215($0.04)($0.02)$11.67 million$11.96 millionViewN/AView Earnings Details
5/7/2015Q115($0.04)($0.05)$10.50 million$10.10 millionViewN/AView Earnings Details
3/4/2015Q414($0.06)($0.03)$9.10 million$9.01 millionViewN/AView Earnings Details
11/4/2014Q214($0.07)($0.05)$7.62 million$7.28 millionViewN/AView Earnings Details
5/7/2014Q114($0.10)($0.13)$5.01 million$4.41 millionViewN/AView Earnings Details
3/5/2014Q413($0.10)($0.11)$4.01 million$4.10 millionViewN/AView Earnings Details
1/30/2014Q4($0.12)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$2.70 million$2.60 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.10)$2.72 million$1.90 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$2.48 million$1.72 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.09)($0.09)$1.50 million$1.38 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Current Year EPS Consensus Estimate: $0.42 EPS
Next Year EPS Consensus Estimate: $0.72 EPS

Dividends

Dividend History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Insider Ownership Percentage: 19.20%
Institutional Ownership Percentage: 61.48%
Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Institutional Ownership by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/19/2017David L MahoneyDirectorSell23,006$12.50$287,575.00View SEC Filing  
7/18/2017David L MahoneyDirectorSell6,091$12.50$76,137.50View SEC Filing  
7/13/2017David L MahoneyDirectorSell6,994$12.50$87,425.00View SEC Filing  
7/12/2017David L MahoneyDirectorSell6,510$12.50$81,375.00View SEC Filing  
5/4/2017Gary Charles RobbCFOBuy5,600$9.75$54,600.00View SEC Filing  
3/16/2017Patrick G. EnrightDirectorSell269,955$9.94$2,683,352.70View SEC Filing  
3/15/2017Patrick G EnrightDirectorSell600,000$10.15$6,090,000.00View SEC Filing  
3/8/2017Patrick G EnrightDirectorSell750,000$9.75$7,312,500.00View SEC Filing  
2/27/2017Patrick G EnrightDirectorSell2,500,000$8.81$22,025,000.00View SEC Filing  
11/25/2016Patrick G EnrightDirectorSell36,941$9.34$345,028.94View SEC Filing  
11/21/2016Patrick G EnrightDirectorSell544,100$9.56$5,201,596.00View SEC Filing  
11/16/2016Patrick G EnrightDirectorSell174,847$9.55$1,669,788.85View SEC Filing  
11/11/2016James N WilsonDirectorSell158,812$8.51$1,351,490.12View SEC Filing  
11/11/2016Joseph K BelanoffInsiderSell500,000$8.98$4,490,000.00View SEC Filing  
11/7/2016Joseph K BelanoffCEOSell500,000$8.31$4,155,000.00View SEC Filing  
5/10/2016G Leonard Baker JrDirectorBuy100,000$4.88$488,000.00View SEC Filing  
1/6/2016James N WilsonDirectorSell1,188$4.90$5,821.20View SEC Filing  
12/10/2015Daniel BradburyDirectorSell20,000$4.85$97,000.00View SEC Filing  
11/24/2015Daniel BradburyDirectorSell40,000$5.00$200,000.00View SEC Filing  
11/12/2015James N WilsonDirectorSell20,000$4.90$98,000.00View SEC Filing  
11/2/2015Steven LoVPSell12,500$4.00$50,000.00View SEC Filing  
10/13/2015Steven LoVPSell53,033$3.82$202,586.06View SEC Filing  
10/7/2015Steven LoVPSell5,300$4.00$21,200.00View SEC Filing  
10/6/2015Steven LoVPSell50,000$3.76$188,000.00View SEC Filing  
9/16/2015Daniel BradburyDirectorSell20,000$4.96$99,200.00View SEC Filing  
9/1/2015James N WilsonDirectorSell10,000$4.90$49,000.00View SEC Filing  
8/27/2015Daniel BradburyDirectorSell20,000$4.76$95,200.00View SEC Filing  
7/21/2015Daniel BradburyDirectorSell10,000$4.98$49,800.00View SEC Filing  
7/20/2015Daniel BradburyDirectorSell10,000$5.32$53,200.00View SEC Filing  
7/8/2015David L MahoneyDirectorSell33,828$5.74$194,172.72View SEC Filing  
7/1/2015James N WilsonDirectorSell10,000$6.06$60,600.00View SEC Filing  
6/24/2015Daniel BradburyDirectorSell20,000$6.75$135,000.00View SEC Filing  
6/23/2015Daniel BradburyDirectorSell10,000$6.92$69,200.00View SEC Filing  
6/2/2015James N WilsonDirectorSell10,000$6.13$61,300.00View SEC Filing  
3/24/2015Patrick G EnrightDirectorSell1,089,745$5.75$6,266,033.75View SEC Filing  
3/19/2015Joseph C Cook JrDirectorSell77,200$5.22$402,984.00View SEC Filing  
6/11/2014G Leonard Baker JrDirectorBuy103,386$2.32$239,855.52View SEC Filing  
5/13/2014Joseph Cook, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/12/2014Daniel BradburyDirectorBuy138,925$1.80$250,065.00View SEC Filing  
5/9/2014G Leonard Baker, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/2/2014Longitude Venture Partners L.PDirectorSell250,000$4.11$1,027,500.00View SEC Filing  
4/1/2014Patrick EnrightDirectorSell250,000$4.28$1,070,000.00View SEC Filing  
3/7/2014Longitude Venture Partners L.PDirectorSell250,000$4.00$1,000,000.00View SEC Filing  
3/14/2013Joseph L TurnerDirectorBuy10,000$2.01$20,100.00View SEC Filing  
12/5/2012G Leonard Baker JrDirectorBuy87,131$1.46$127,211.26View SEC Filing  
11/23/2012Daniel BradburyDirectorBuy179,000$1.39$248,810.00View SEC Filing  
11/7/2012G Leonard Baker JrDirectorBuy300,000$1.83$549,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Latest Headlines for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Source:
DateHeadline
nasdaq.com logoInteresting CORT Put And Call Options For May 2018
www.nasdaq.com - September 20 at 6:12 PM
finance.yahoo.com logo4 Biotech Stocks That Show Promise on Sustainable Growth
finance.yahoo.com - September 14 at 6:15 PM
americanbankingnews.com logoReviewing Corcept Therapeutics (CORT) & Cambrex Corporation (CBM)
www.americanbankingnews.com - September 11 at 4:10 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 9 at 2:50 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) PT Raised to $24.00
www.americanbankingnews.com - September 8 at 12:02 PM
americanbankingnews.com logoStifel Nicolaus Initiates Coverage on Corcept Therapeutics Incorporated (CORT)
www.americanbankingnews.com - August 31 at 12:34 PM
nasdaq.com logoPfizer's sNDA for Bosulif Accepted in the U.S. and Europe
www.nasdaq.com - August 30 at 6:29 PM
finance.yahoo.com logoPfizer's sNDA for Bosulif Accepted in the U.S. and Europe
finance.yahoo.com - August 30 at 6:28 PM
finance.yahoo.com logoTop Ranked Momentum Stocks to Buy for August 29th
finance.yahoo.com - August 29 at 5:52 PM
finance.yahoo.com logoCramer's lightning round: I know I'm alone here, but I still like the airlines
finance.yahoo.com - August 28 at 10:21 PM
finance.yahoo.com logoAdamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars
finance.yahoo.com - August 25 at 3:34 PM
finance.yahoo.com logoMylan and Otsuka Ink Agreement to Commercialize Deltyba
finance.yahoo.com - August 25 at 3:34 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Given a $18.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - August 24 at 6:28 PM
americanbankingnews.com logoAegerion Pharmaceuticals (AEGR) vs. Corcept Therapeutics (CORT) Financial Survey
www.americanbankingnews.com - August 21 at 10:26 AM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Upgraded by BidaskClub to Strong-Buy
www.americanbankingnews.com - August 19 at 12:24 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Corcept Therapeutics Inc. and Opko Health Inc.
finance.yahoo.com - August 18 at 5:27 PM
nasdaq.com logoThree Stocks Breaking Out - Nasdaq
www.nasdaq.com - August 18 at 4:45 AM
finance.yahoo.com logoThree Stocks Breaking Out
finance.yahoo.com - August 16 at 5:50 PM
finance.yahoo.com logoThree Breakouts, And One Possible Breakdown In Cummins
finance.yahoo.com - August 16 at 5:50 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Expected to Post Earnings of $0.14 Per Share
www.americanbankingnews.com - August 16 at 6:30 AM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 15 at 6:32 PM
nasdaq.com logoWhy Corcept Therapeutics (CORT) Could Be Positioned for a Surge - Nasdaq
www.nasdaq.com - August 14 at 5:49 PM
finance.yahoo.com logoWhy Corcept Therapeutics (CORT) Could Be Positioned for a Surge
finance.yahoo.com - August 14 at 5:49 PM
finance.yahoo.com logoCan The Uptrend Continue for Corcept Therapeutics (CORT)?
finance.yahoo.com - August 9 at 5:35 PM
finance.yahoo.com logoTop Ranked Momentum Stocks to Buy for August 7th - Yahoo Finance
finance.yahoo.com - August 9 at 3:10 AM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - August 6 at 11:56 AM
globenewswire.com logoCorcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and ... - GlobeNewswire (press release)
globenewswire.com - August 3 at 4:24 AM
fool.com logoWhy Corcept Therapeutics Incorporated Stock Surged Higher Today - Motley Fool
www.fool.com - August 3 at 4:24 AM
finance.yahoo.com logoEdited Transcript of CORT earnings conference call or presentation 1-Aug-17 9:00pm GMT
finance.yahoo.com - August 2 at 11:20 PM
fool.com logoWhy Corcept Therapeutics Incorporated Stock Surged Higher Today
www.fool.com - August 2 at 7:32 PM
finance.yahoo.com logoCorcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised
finance.yahoo.com - August 2 at 6:15 PM
finance.yahoo.com logoHow These 2 Biotechs Defied The Downtrend To Hit Fresh Highs
finance.yahoo.com - August 2 at 6:15 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (NASDAQ:CORT) Issues Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - August 2 at 2:42 PM
rttnews.com logoFDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount
www.rttnews.com - August 2 at 4:07 AM
finance.yahoo.com logoCorcept beats 2Q profit forecasts
finance.yahoo.com - August 1 at 11:05 PM
finance.yahoo.com logoCorcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
finance.yahoo.com - August 1 at 6:05 PM
finance.yahoo.com logoETFs with exposure to Corcept Therapeutics, Inc. : August 1, 2017
finance.yahoo.com - August 1 at 6:05 PM
finance.yahoo.com logo3 Under-the-Radar Stocks in the Healthcare Sector
finance.yahoo.com - July 26 at 6:01 PM
nasdaq.com logoCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference ... - Nasdaq
www.nasdaq.com - July 25 at 5:22 PM
finance.yahoo.com logoCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
finance.yahoo.com - July 25 at 5:22 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) to Release Earnings on Monday
www.americanbankingnews.com - July 24 at 8:41 AM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Upgraded to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - July 23 at 11:50 PM
americanbankingnews.com logoDavid L. Mahoney Sells 6,091 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - July 21 at 7:51 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 21 at 6:50 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Director Sells $287,575.00 in Stock
www.americanbankingnews.com - July 20 at 10:24 PM
fool.com logoIs It Too Late to Get In on This Millionaire-Maker Stock?
www.fool.com - July 16 at 6:42 AM
americanbankingnews.com logoDavid L. Mahoney Sells 6,994 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - July 14 at 8:46 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (NASDAQ:CORT) Director David L. Mahoney Sells 6,510 Shares
www.americanbankingnews.com - July 14 at 8:46 PM
zacks.com logoCorcept Therapeutics Focuses on Korlym's Label Expansion
www.zacks.com - July 13 at 6:31 PM
finance.yahoo.com logoCorcept Therapeutics Focuses on Korlym's Label Expansion
finance.yahoo.com - July 13 at 6:30 PM

Social

Chart

Corcept Therapeutics Incorporated (CORT) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff